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SIVs	infecting	wild-living	apes	in	west	central	Africa	have	crossed	the	species	barrier	to	humans	on	at	least	four	
different	occasions,	one	of	which	spawned	the	AIDS	pandemic.	Although	the	chimpanzee	precursor	of	pan-
demic	HIV-1	strains	must	have	been	able	to	infect	humans,	the	capacity	of	SIVcpz	strains	to	replicate	in	human	
lymphoid	tissues	(HLTs)	is	not	known.	Here,	we	show	that	SIVcpz	strains	from	two	chimpanzee	subspecies	are	
capable	of	replicating	in	human	tonsillary	explant	cultures,	albeit	only	at	low	titers.	However,	SIVcpz	replication	
in	HLT	was	significantly	improved	after	introduction	of	a	previously	identified	human-specific	adaptation	at	
position	30	in	the	viral	Gag	matrix	protein.	An	Arg	or	Lys	at	this	position	significantly	increased	SIVcpz	repli-
cation	in	HLT,	while	the	same	mutation	reduced	viral	replication	in	chimpanzee-derived	CD4+	T	cells.	Thus,	
naturally	occurring	SIVcpz	strains	are	capable	of	infecting	HLTs,	the	major	site	of	HIV-1	replication	in	vivo.	
However,	efficient	replication	requires	the	acquisition	of	a	host-specific	adaptation	in	the	viral	matrix	protein.	
These	results	identify	Gag	matrix	as	a	major	determinant	of	SIVcpz	replication	fitness	in	humans	and	suggest	a	
critical	role	in	the	emergence	of	HIV/AIDS.
Introduction
AIDS, one of the most devastating infectious diseases that have 
emerged recently, is the result of zoonotic transmissions of viruses 
naturally infecting primates in Africa. It is now well established 
that HIV-1, the main cause of AIDS, emerged as a consequence of 
at least 4 cross-species transmissions of SIVs infecting wild-living 
apes (1, 2). Both SIVcpz-infected chimpanzees (Pan troglodytes trog-
lodytes) and SIVgor-infected gorillas (Gorilla gorilla gorilla) transmit-
ted their viruses to humans, generating HIV-1 groups M, N, O, and 
P (1–4). Of these, groups, M and N have been traced to geographi-
cally isolated chimpanzee communities in southeastern Camer-
oon (3). Group P appears to be of gorilla origin (4, 5), while the ape 
source of group O has not yet been defined (6). Although members 
of all 4 HIV-1 lineages can cause CD4+ T cell decline and AIDS, the 
extent of their spread in the human population has been very dif-
ferent. Group M is by far the most prevalent and has infected over 
60 million individuals worldwide. Group O accounts for less than 
1% of AIDS cases and is largely restricted to Cameroon, Gabon, 
and neighboring countries (7, 8). Groups N and P are much rarer 
still and have been found in only 17 and 2 individuals, all but 1 
from Cameroon, respectively (4, 5, 9, 10). The reasons underlying 
this extreme variation in distribution of the 4 groups are poorly 
understood, but most likely involve differences in the degree of 
adaptation to the new human host (11).
Like other viruses, primate lentiviruses must utilize numerous 
host proteins and counteract a variety of innate restriction fac-
tors in order to replicate efficiently in their respective hosts (11, 
12). Many cellular factors vary among different species (13), and 
it is thus not surprising that viruses tend to cross more readily 
between more closely related host species (14, 15). However, even 
the genomes of very closely related species, such as humans and 
chimpanzees, exhibit multiple differences (16, 17). To define how 
these differences may have influenced the zoonotic potential of 
ape lentiviruses, we have begun to look for host-specific adap-
tations. In a previous study, we searched SIVcpz proteomes for 
sites that were highly conserved in the ape precursors of HIV-1, 
but changed — in the same way — each time these viruses crossed 
the species barrier to humans. This analysis identified one site in 
the viral matrix protein (Gag30) that encoded a Met or Leu in all 
known strains of SIVcpz and SIVgor, but switched to an Arg in the 
inferred ancestors of HIV-1 groups M, N, and O and to a Lys in 
many current pandemic HIV-1 strains (18). We also noted that an 
HIV-1 strain that had been extensively passaged in chimpanzees 
underwent a reversion of this host-specific signature (19). When 
molecular clones of this virus were tested for replication in chim-
panzee CD4+ T cells, only those that encoded a Met at Gag30 rep-
licated efficiently, whereas isogenic controls that encoded a Lys at 
Gag30 did not, while the opposite was observed in human CD4+ 
T cells (18). These results suggested that the amino acid at position 
30 in the viral matrix protein has been under strong host-specific 
selection pressure. However, the impact of Gag30 on the ability of 
SIVcpz strains to replicate in HLTs, the major site of viral replica-
tion in infected humans, was not assessed.
To determine more directly the extent to which the amino acid 
residue at Gag30 influences the zoonotic potential of ape SIVs, we 
used noninvasive methods to generate a panel of infectious SIVcpz 
clones and examined their ability to replicate in human lymphoid 
tissues (HLTs) in the presence and absence of the species-specific 
signature. In addition to lymphocyte cultures, we selected human 
tonsil tissue to examine viral replication fitness, since these cul-
tures do not require exogenous activation for viral infection (20, 
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21). Moreover, tonsil cultures maintain their cell complexity and 
cytoarchitecture and are thus more likely to recapitulate condi-
tions of viral growth and transmission in vivo (20, 21). Analyzing 
4 genetically diverse SIVcpz strains, including the closest relatives 
of HIV-1 groups M and N, we found that all chimpanzee viruses 
were capable of infecting and replicating in HLTs, albeit at lower 
titers than HIV-1 strains. However, introduction of the human-
specific Gag30 substitution significantly increased their growth 
potential in HLT cultures (P < 0.0001). Thus, naturally occurring 
SIVcpz strains were capable of infecting HLT, but host-specific 
adaptations were required to enhance viral replication fitness and 
ensure successful colonization of humans.
Results
To examine the growth kinetics of chimpanzee lentiviruses in 
human CD4+ T cells and lymphatic tissues, we generated a panel of 
replication-competent molecular clones of SIVcpz from wild-liv-
ing chimpanzees. This was accomplished as previously described 
by synthesizing viral consensus sequences amplified from fecal 
samples of naturally infected apes (3, 6, 22, 23). Three of these 
viruses were derived from members of the central chimpanzee 
subspecies (P.t. troglodytes) sampled in Cameroon (MT145, MB897, 
and EK505), while the fourth strain was obtained from an east-
ern chimpanzee (Pan troglodytes schweinfurthii) sampled in Tanza-
nia (TAN2) (Table 1). Importantly, SIVcpzPtt strains MB897 and 
EK505 represent the closest genetic relatives of HIV-1 groups M 
and N, respectively, while SIVcpzPts strain TAN2 is highly diver-
gent from all HIV-1 groups and represents a viral lineage that 
has never been found in humans (Figure 1). For control, we also 
examined reference strains of HIV-1 (NL4-3, JRCSF, SG3, YU2) as 
well as 2 HIV-1 clones (JC16 and NC7) that were obtained after 
prolonged in vivo passage in chimpanzees (refs. 19, 24–29, and 
Table 1). To account for differences in coreceptor usage, we also 
included a CCR5-tropic version of NL4-3 (25). Finally, we obtained 
site-directed mutants of all of these viruses by introducing species-
specific signatures at position 30 of the p17 matrix protein (18). 
In all SIVcpz constructs and in the chimpanzee-adapted JC16 and 
NC7 clones, Gag30 was changed from a hydrophobic Met or Leu 
residue to a basic Arg or Lys residue, while reciprocal changes were 
introduced in all reference strains of HIV-1 (for NL4-3, both Met 
and Leu containing mutants were generated).
To examine early infection events, viral stocks were generated 
by transfection of 293T cells and used to infect TZM-bl cells, 
which express high levels of the HIV/SIV receptor (CD4) and 
coreceptors (CCR5 and CXCR4). TZM-bl cells also contain LTR-
driven β-galactosidase and luciferase reporter cassettes that are 
activated by Tat expression (30, 31). Using viral stocks that were 
equilibrated by p24 content, we found that all viruses were capa-
ble of infecting TZM-bl cells, albeit to varying degrees (Figure 
2A). Overall, HIV-1 strains resulted in significantly higher (Tat-
Table 1
HIV-1 and SIVcpz infectious molecular clones analyzed
Clone	 Origin	 Species/subspecies	 Source	 	Gag	p17	 Accession	 	Reference
EK505 SIVcpzPtt Central chimpanzee (P.t.t.) Fecal viral RNA M30 JN835460 3
MB897 SIVcpzPtt Central chimpanzee (P.t.t.) Fecal viral RNA M30 JN835461 23
MT145 SIVcpzPtt Central chimpanzee (P.t.t.) Fecal viral RNA M30 JN835462 3
TAN2 SIVcpzPts Eastern chimpanzee (P.t.s.) Fecal viral RNA L30 DQ374657 22
JC16 HIV-1 Chimpanzee-adapted Primary PBMC culture M30 AF049494 19
NC7 HIV-1 Chimpanzee-adapted Primary PBMC culture M30 AF049495 19
NL4-3 HIV-1/M Human Immortalized T cell line K30 U26942 24
R5 NL4-3 HIV-1/M Human Contains V3 loop of 92TH014 K30 NA 25
SG3 HIV-1/M Human Immortalized T cell line K30 L02317 26
YU-2C HIV-1/M Human Uncultured brain tissue R30 M89973 27, 28
JR-CSF HIV-1/M Human Primary PBMC culture R30 M38429 29
P.t.t., P.t. troglodytes; P.t.s., P.t. schweinfurthii; NA, not available.
Figure 1
Evolutionary relationships of HIV-1 (including groups M, N, O, and P), 
SIVcpzPtt (upper clade) and SIVcpzPts (lower clade), and SIVgor Gag 
protein sequences, shown in red, blue, and green, respectively. The 
4 molecular clones of SIVcpz analyzed in this study are highlighted in 
yellow. The tree was constructed using maximum likelihood methods 
*Bootstrap support of greater than 80%. Scale bar: 0.1 amino acid 
replacements per site.
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driven) β-galactosidase activity than SIVcpz strains (Figure 2B), 
indicating that they were able to enter TZM-bl cells and integrate 
their proviral genomes more efficiently. However, changing a 
Met or Leu at Gag30 to an Arg increased the infectiousness of 
SIVcpz by 2.5-fold, while the reciprocal mutations (K/R30M/L) 
in HIV-1 strains reduced their infectivity (Figure 2B). The 
effect of mutations at Gag30 in WT HIV-1 and SIVcpz strains 
was highly significant (Figure 2C), although the magnitude 
was strain dependent. For example, a K30M change impaired 
the infectiousness of the HIV-1 strains JRCSF and YU2C, but 
had little effect on SG3. Similarly, the reciprocal M30R change 
enhanced the infectiousness of the SIVcpz strains EK505 and 
MB897 more significantly than that of MT145 (Figure 2A).
We previously reported that chimpanzee-adapted HIV-1 strains 
encoding Met instead of Lys or Arg at Gag30 had a growth 
advantage in chimpanzee, but not human, CD4+ T cells (18). To 
examine the effect of Gag30 on viral replication in cells from dif-
ferent hosts, we compared WT and mutant SIVcpz and HIV-1 
constructs in human and chimpanzee CD4+ T lymphocytes. 
Interestingly, we found that K/R30M/L mutations had little, if 
any, effect on the replication fitness of HIV-1 in human CD4+ 
T cells (Figure 3A). This was also true for SIVcpz strains, which 
replicated to similar titers regardless of whether they encoded 
a WT Gag30 residue or the human K/R adaptation (Figure 
3A). Direct competition experiments confirmed this, revealing 
roughly equal ratios of WT and mutant viruses in most CD4+ 
T cell cultures 7 days after infection, although in some cultures, 
viruses containing the human-specific Arg or Lys residue became 
predominant (examples shown in Figure 3B). In contrast, a chim-
panzee-specific Met or Leu was usually required for efficient viral 
growth in chimpanzee-derived CD4+ T cells. This was particularly 
true for SIVcpz strains MB897 and EK505, where a human-spe-
cific Arg residue caused a severe fitness loss in chimpanzee CD4+ 
T cells (Figure 3A). An Arg-to-Met substitution was also essential 
for replication of the HIV-1 strain JRCSF in chimpanzee T cells, 
but had only marginal effects on the growth of SG3 and YU2C 
(Figure 3C). On average, the WT (R/K) HIV-1 constructs replicat-
ed significantly (P = 0.0006) more efficiently in human-derived 
than in chimpanzee-derived T cells, whereas WT (M/L) SIVcpz 
constructs replicated with similar efficacy in cells from both spe-
cies (Figure 3D). However, an Arg at Gag30 caused a significant 
reduction in SIVcpz replication in chimpanzee cells (50.2 ± 10.0%; 
Figure 2
Infectivity of WT and Gag30 mutant HIV-1 and SIVcpz strains in TZM-bl cells. (A) TZM-bl indicator cells were infected with WT and Gag30 mutant 
SIVcpz and HIV-1 constructs as indicated. Infections were performed in triplicate with virus stocks containing 1 ng of p24 antigen (average 
values ± SDs are shown). CPZa, chimpanzee adapted. (B) Relative infectivity of WT and Gag30 mutant HIV-1 and SIVcpz constructs. Shown 
are minimum and maximum values, 25% and 75% percentiles, and median values. (C) Modulation of viral infectivity by host-specific adaptation 
at Gag30. Changing a Lys or Arg to a Met or Leu reduced the infectivity of HIV-1 by 50%, while the reciprocal mutations more than doubled the 
infectivity of SIVcpz. Values are shown in relation to those of the corresponding parental HIV-1 or SIVcpz constructs set to 100%.
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P = 0.0009; n = 24), while a modest enhancement was observed in 
human CD4+ T cells (141.1 ± 23.5%; P = 0.0094; n = 16) (Figure 
3E). Interestingly, the HIV-1 group M and N relatives MB897 and 
EK505 replicated substantially more efficiently than MT145 and 
TAN2 in human, but not in chimpanzee, cells (Figure 3C).
The fact that a basic residue at Gag30 emerged independently in 
all groups of HIV-1 (18), including 1 of the 2 known group P viruses 
(4, 5), suggested that it conferred a significant fitness advantage in 
human cells. It was thus surprising to find that introduction of this 
adaptive change into 4 SIVcpz genomes had little effect on their rep-
Figure 3
Replication potential of WT and Gag30 mutant HIV-1 and SIVcpz in human and chimpanzee CD4+ T lymphocytes. (A) Replication kinetics are 
shown for isogenic pairs of WT and Gag30 mutant HIV-1 (red) and SIVcpz (green) clones in human (HU) and chimpanzee (CPZ) CD4+ T lym-
phocytes. Each virus pair was tested in cells from 6 chimpanzee and 4 human donors by measuring RT activity in culture supernatants (one 
representative curve is shown). (B) Competition of WT and Gag30 mutant HIV-1 and SIVcpz constructs. Human CD4+ T cells were infected with 
virus stocks that were normalized for p24 content and mixed at a 1:1 ratio. Sequence chromatograms of RT-PCR amplification products obtained 
from the input virus and cell culture supernatants collected at 7 days after infection are shown. (C) Cumulative virus production over 13 days of 
culture in CD4+ T lymphocytes from 4 human (left) and 6 chimpanzee (right) donors infected with the indicated HIV-1 or SIVcpz variants. Data are 
shown as mean ± SEM. (D) Mean production of HIV-1 or SIVcpz constructs containing an R/K or M/L at Gag30 in human- or chimpanzee-derived 
CD4+ T cells. Data are shown as mean ± SEM obtained for all 3 HIV-1 and 4 SIVcpz strains analyzed. (E) Replication of SIVcpz M/L30R mutants 
in human and chimpanzee cells. Cumulative RT production levels of the Gag30 mutants are shown in relation to those of their parental constructs 
set to 100%. WT JRCSF and YU2C strains did not replicate at detectable levels in most chimpanzee cells, thus precluding a direct comparison.
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lication potential in human-derived CD4+ T cells (Figure 3). Lym-
phocyte cultures are maximally stimulated and thus do not reflect 
conditions of viral growth in vivo. Human tonsil explant cultures 
support HIV-1 replication without exogenous stimulation and 
largely maintain the complexity of cell populations and tissue archi-
tecture (20, 21). We thus reasoned that this culture system might be 
more appropriate for examining the replicative capacity of SIVcpz 
strains in HLTs. Human tonsils were dissected, set up in culture, 
and infected as described previously (20, 21). The results showed 
that M30K or M30R changes increased the replication potential 
of SIVcpz and chimpanzee-adapted HIV-1 strains in this culture 
system, while R30M or K30L/M changes decreased the replication 
potential of HIV-1 strains (Figure 4, A and B). Again, the effect of the 
Gag30 changes on viral replication was strain dependent and most 
pronounced in SIVcpz strain EK505, where a Met to Arg change at 
position 30 increased the ability of this virus to replicate in human 
tissue about 4-fold. Notably, changing Lys to Leu, which is the pre-
dominant amino acid among known SIVcpzPts strains, reduced the 
Figure 4
Replication kinetics of WT and Gag30 mutant HIV-1 and SIVcpz in human tonsil explant cultures. (A) Representative growth curves of WT and 
Gag30 mutant HIV-1, CPZ-adapted HIV-1 (CPZa), and SIVcpz constructs. Infections were performed in triplicate. Data shown are average values 
± SD. (B) Virus production by tonsillary explant cultures infected with SIVcpz and HIV-1 constructs. Cumulative virus production is shown over 14 
days. Matched tissues from 7 to 12 donors were inoculated with the WT HIV-1 (left), chimpanzee-adapted HIV-1 (middle). and SIVcpz (right) con-
structs or with their respective Gag30 mutants, and for each HLT culture, virus production was measured over 14 days. Data are shown as mean ± 
SEM. (C) Average cumulative p24 antigen levels in HLT cultures from 7 to 12 donors. Data are shown as mean ± SEM. (D) Host-specific adaptation 
increases replication fitness. Mutation of K/R30M/L reduces HIV-1 replication, and substitution of M/L30R increases SIVcpz replication in HLTs. 
Cumulative p24 antigen production levels of the Gag30 mutants are shown in relation to those of their respective parental constructs set to 100%.
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replicative potential of HIV-1 NL4-3 more severely than a substitu-
tion to Met, found in most SIVcpzPtt strains (Figure 4B). On average, 
WT HIV-1 strains produced 5-fold higher cumulative levels of p24 
antigen than WT SIVcpz strains in HLTs (Figure 4C). Introduction 
of a chimpanzee-specific Met or Leu into HIV-1 constructs reduced 
p24 production in HLT to 54% ± 6% (n = 19) of WT levels (Figure 4C). 
In contrast, introduction of a human-specific Arg into SIVcpz con-
structs increased virus production to 200% ± 33% (n = 11) of WT levels 
(Figure 4D). As expected, the negative effect of a Met or Leu at Gag30 
on the replication potential of both HIV-1 and SIVcpz was more 
pronounced in ex vivo–infected HLT than in human CD4+ T cell 
cultures (Supplemental Figure 1A; supplemental material available 
online with this article; doi:10.1172/JCI61429DS1), although there 
was a significant correlation between the magnitude of the disruptive 
effect in the 2 culture systems for each strain (Supplemental Figure 
1B). In summary, the results showed that SIVcpz constructs contain-
ing human Gag30 signatures replicated considerably more efficient-
ly in ex vivo HLT than WT SIVcpz, suggesting a key role in human 
adaptation. It should be noted, however, that this change was not 
sufficient to raise SIVcpz replication levels to those of contemporary 
HIV-1 strains, since HIV-1 WT constructs still produced 3-fold high-
er amounts of p24 than SIVcpz 
containing the Arg Gag30 sub-
stitution (Figure 4C).
To quantify the effect of an 
Arg residue at Gag30 on viral 
replication fitness in human 
cells, we performed a series of 
competition experiments in ex 
vivo HLTs. Stocks of WT and 
mutant viruses were mixed in 
equal ratios and used to infect 
the tonsil explant cultures. 
Virus production was then 
monitored by RT-PCR followed 
by direct sequencing of the p17 
coding region that encompass-
es Gag30. Since WT and mutant HIV-1 and SIVcpz clones differ by 
only 1 or 2 nucleotides within the Gag30 codon, PCR amplifications 
were unbiased with respect to these mutations. Direct sequence 
analysis of amplification products indicated that the fluorescence 
levels of WT and mutant nucleotides reflected their input ratios and 
thus allowed the generation of standard curves (Figure 5A). We then 
analyzed equal mixtures of isogenic WT and Gag30 mutant before 
and after culture in tonsil explant cultures. The results showed that 
WT and mutant viruses were present at similar ratios (46% to 54%) 
in the infection stock (Figure 5B). However, after 2 weeks of HLT cul-
ture, viruses containing an Arg or Lys residue at Gag30 outcompeted 
those that encoded a Met or Leu residue (Figure 5B and Table 2). This 
selection bias for a basic residue at Gag30 resulted in a significantly 
higher percentage of viral sequences encoding Arg or Lys than Met 
or Leu (Supplemental Figure 2A). Notably, the proportion of HIV-1 
and SIVcpz constructs containing M/L at Gag30 at the end of the 
competition experiments correlated with their relative replication 
fitness in ex vivo–infected HLTs (Supplemental Figure 2B). Thus, a 
basic residue at position 30 of the p17 matrix protein can increase 
SIVcpz replication fitness in human lymphoid cultures up to 5-fold, 
although the magnitude of this effect is clearly strain specific.
Figure 5
Host-specific adaptation at Gag30 enhances SIVcpz rep-
lication fitness in ex vivo HLTs. (A) Detection of WT and 
mutant sequences in viral mixtures. Left: WT and K30M 
mutant HIV-1 NL4-3 stocks were normalized for p24 con-
tent, mixed at different ratios as indicated, and sequenced 
directly. Right: example for a standard curve. The peak 
fluorescence of the 2 WT A residues is expressed as a 
fraction of the total fluorescence. (B) Sequence chromato-
grams of mixed viral cultures at input and 14 days after 
infection. Percentages of WT and mutant sequences pro-
vided in B were estimated from standard curves. Values of 
less than 10% may represent nonspecific background.
Table 2
Selective advantage of HIV-1 and SIVcpz constructs encoding R/K at Gag30
Strain	 X4	NL4-3	 X4	NL4-3	 SG3	 R5	NL4-3	 JRCSF	 YU2C
In (1:1) WT/K30L WT/K30M WT/K30M WT/K30L WT/R30M WT/R30M
14 dpi WT (≥90%) WT (65%) WT (56%) WT (≥90%) WT (86%) WT (≥90%)
Strain	 JC16	 NC7	 EK505	 MT145	 MB897	 TAN2
In (1:1) WT/M30K WT/M30K WT/M30R WT/M30R WT/M30R WT/L30R
14 dpi M30K (70%) M30K (77%) M30R (89%) M30R (78%) M30R (63%) L30R (88%)
A basic residue (R or K) at Gag30 increases the fitness of HIV-1 and SIVcpz in HLTs. Tissues were infected with 
virus stocks containing the indicated WT and Gag30 mutant viruses at a 1:1 ratio (normalized by p24 content). RNA 
was extracted from the virus stocks used for infection and the HLT supernatants obtained at 14 days after infection 
were subjected to RT-PCR of the gag coding region and analyzed by direct sequencing. Percentages of WT and 
mutant sequences were estimated from standard curves. In, inoculum; dpi, days post infection.
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Discussion
SIV infection is endemic in wild-living apes throughout equato-
rial Africa, yet only certain lineages of SIVcpz and SIVgor have 
been found to infect and cause disease in humans (1–3). This has 
raised the question of whether certain strains of SIVcpz/SIVgor are 
more prone than others to cross from apes to humans. Although 
all SIVcpz and SIVgor strains identified to date grow efficiently 
in human CD4+ T cells (6, 22), these maximally activated cultures 
are unlikely to represent a reliable surrogate of zoonotic poten-
tial. In the present study, we show that 4 genetically diverse SIVcpz 
strains from both central and eastern chimpanzees are capable 
of establishing a productive infection in HLT, the major site of 
HIV-1 replication in vivo. This is remarkable, given the number of 
different host proteins and innate restriction factors that primate 
lentiviruses must utilize or counteract (11, 32–34) and suggests 
that most (if not all) SIVcpz strains have the biological properties 
required for cross-species infection of humans. However, replica-
tion fitness of SIVcpz doubled upon the introduction of a previ-
ously identified human signature at position 30 of the viral matrix 
protein. Thus, even chimpanzee-to-human transmission seems to 
impose substantive adaptive hurdles to ape lentiviruses.
Although replacement of Met/Leu with Arg at Gag30 enhanced 
the replication potential of all 4 SIVcpz strains in HLTs, their over-
all growth rates still remained 3-fold lower than those of the HIV-1 
strains, indicating additional adaptations. One of these likely includes 
effective antitetherin activity. Tetherin (also termed Bst-2) inhibits the 
release of virions from infected cells by “tethering” them at the plasma 
membrane (35, 36). Like most primate lentiviruses, SIVcpz uses its 
Nef protein to antagonize tetherin (37–39). However, the SIVcpz Nef 
protein is inactive against human tetherin due to a 5–amino acid dele-
tion in the cytoplasmic domain of the human protein that confers 
resistance to Nef binding (37–39). This lack of antitetherin activity 
must explain, at least in part, why SIVcpz constructs containing the 
human Gag30 adaptation still replicate less efficiently than HIV-1 
strains in HLT cultures. In fact, previous studies have shown that a 
defective vpu gene decreased replication of HIV-1 in ex vivo–infected 
human tonsillary tissue by about 3-fold, although it was not deter-
mined whether this reduction was due to lack of antitetherin activity 
or other Vpu functions, such as degradation of CD4 (40). Nonethe-
less, the results suggest that effective tetherin antagonism may be 
required for efficient replication of SIVcpz in HLTs.
Current data suggest that a fitness gain at Gag30 was a prerequisite 
for the emergence of HIV-1 groups M, N, and O. The fact that only 1 
of the 2 recently discovered HIV-1 group P strains has switched from 
a Met to a Lys at Gag30 is interesting, since this could indicate that 
this group is still in the process of adaptation (41, 42). However, a 
single amino acid change at Gag30 seems easier to achieve than the 
acquisition of a new antitetherin function. Pandemic HIV-1 group M 
was able to master this by switching from Nef- to Vpu-mediated teth-
erin antagonism (38). However, this did not happen in HIV-1 groups 
O and P, whose Vpu proteins failed to gain this function (38, 39, 41, 
42). The Vpu protein of HIV-1 group N gained some antitetherin 
activity, but lost its ability to degrade CD4. Thus, it is tempting to 
speculate that the adaptive change in Gag30 was a necessary first 
step to increase the replication potential of SIVcpz in HLTs such that 
additional mutations could subsequently accumulate to facilitate 
the gain of antitetherin function by its vpu gene.
Although SIVcpz is endemic in both central and eastern chim-
panzees, only SIVcpzPtt strains have thus far been found in humans 
(1–3, 43). It is possible that humans are less frequently exposed to 
SIVcpz-infected eastern chimpanzees or that SIVcpzPts strains have 
been transmitted but gone unrecognized. However, it is also pos-
sible that SIVcpzPts strains are inherently less fit to infect humans. 
We found that the SIVcpzPts strain TAN2 produced about 2-fold 
lower viral titers in HLTs than the SIVcpzPtt strains MT145 and 
MB897 (Figure 4). Moreover, changing Gag30 from Lys to Leu, 
which is found in TAN2, impaired the replication of HIV-1 NL4-3 
in HLT more severely than a change to Met found in all SIVcpz-
Ptt strains (Figure 4). However, not all SIVcpzPtt strains replicated 
efficiently in HLT (Figure 4), and a recent molecular epidemiologi-
cal study in the Democratic Republic of the Congo revealed that 
a number of SIVcpzPts strains encode Met at Gag30, as found in 
SIVcpzPtt (B.H. Hahn, unpublished observations). Thus, neither 
poor replication potential in HLTs nor coding differences at Gag30 
can explain the absence of SIVcpzPts zoonotic infections. Further 
studies will need to define whether certain adaptations, such as the 
acquisition of antitetherin activity, may be more difficult to achieve 
for viruses endemic in eastern chimpanzees.
The mechanism or mechanisms of the Gag30-mediated effect on 
viral replication fitness remain to be determined. The MA protein is 
not only a structural component of the virion, but is also involved 
in viral entry/uncoating, cytoskeletal-mediated transport, nuclear 
import, virion assembly, and incorporation of the viral envelope gly-
coprotein into progeny virions (44, 45), interacting with as many as 
20 different cellular proteins (34). These include 3 of the 4 clathrin 
adaptor protein complexes, AP-1, AP-2, and AP-3 (46–48), the micro-
tubule-associated cellular motor protein KIF4 (49), calmodulin (50), 
47-kDa tail interacting protein (TIP47) (51), elongation factor 1-α 
(EF1α) (52), the virion-associated nuclear shuttling protein (VAN) 
(53), and the barrier-to-autointegration factor (BAF) (54). Among 
these proteins, calmodulin, EF1α, BAF, AP-1 μ1A chain, and AP-2 
μ2 chain are all predicted to be identical between chimpanzees and 
humans and thus unlikely to be responsible for the species-specific 
selection pressure. The chimpanzee and human AP-3 δ chain, TIP47, 
and VAN proteins differ by 3 or 4 amino acids, respectively, while the 
KIF4 motor protein is the most divergent, exhibiting 7.2% amino acid 
difference between human and chimpanzee homologs. Previous stud-
ies have shown that the AP-3 δ chain is involved in Gag trafficking, 
TIP47 mediates Env incorporation into particles, and VAN and KIF4 
may play a role during postentry steps (48, 50, 52, 54). It is possible 
that Gag30, which is located in one of the N-terminal helices of MA, 
interacts with one or more of these proteins or with as-yet-unidenti-
fied host factors and may thus influence steps early in the viral life 
cycle. It should be noted, however, that the magnitude of the effect of 
Gag30 on viral fitness is strain dependent. Thus, as-yet-unidentified 
changes in the MA protein or elsewhere in the viral genome might 
minimize or even remove the need for a basic residue at Gag30.
The fact that we found a much less pronounced effect of Gag30 
on the growth potential of SIVcpz in human CD4+ T cell cultures is 
not surprising. Fully activated CD4+ T cells represent optimal, albeit 
artificial, targets for viral replication. For example, they may express 
MA-interacting proteins at levels different from target cells that are 
not fully activated by exogenous stimuli. T cell activation is known 
to be associated with complex changes of the plasma membrane, the 
cytoplasm, the cytoskeleton and at the nucleus (55), all of which may 
minimize the dependency on MA protein functions. The mode of 
virus spread in the culture, i.e., cell-free versus cell-cell, may also have 
an impact on the magnitude of the Gag30 function. Perhaps most 
importantly, effective spread of HIV-1 and SIVcpz in vivo involves 
a complex interplay between different types of virally infected and 
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noninfected cells, which are more accurately represented by lym-
phoid tissues than stimulated CD4+ T lymphocyte cultures. Thus, 
our finding that a basic residue significantly increases the replica-
tion fitness of SIVcpz strains in HLT strongly suggests that it is also 
relevant for viral replication and transmission in vivo.
In summary, our results demonstrate that nonadapted SIVcpz 
strains can replicate to some extent in HLTs. We also show that 
the acquisition of a basic residue at Gag30 in the viral matrix pro-
tein significantly increased the replication fitness of SIVcpz in the 
new human host, albeit not to the levels of current HIV-1 group 
M strains. Thus, additional changes, such as the development of 
effective tetherin antagonism, were required to achieve full repli-
cation fitness. Since exposures of humans to ape lentiviruses are 
likely to continue, further analyses of host-specific adaptation will 
be important to assess the future human zoonotic risk.
Methods
HIV-1 and SIVcpz constructs. HIV-1 clones NL4-3, SG3, YU2, and JRCSF as well 
as SIVcpzPts clone TAN2 have been reported (refs. 21–28 and Table 1). To gen-
erate the SIVcpzPtt clones MT145, EK505, and MB897, subgenomic regions 
of the viral genome were amplified from fecal samples and sequenced direct-
ly; their consensus sequences were synthesized in 2 (MT145 and EK505) or 3 
(MB897) fragments, which were then concatenated (Blue Heron Biotechnol-
ogy). To enable directional cloning, unique restriction sites were added to the 
5′ and 3′ termini of the proviruses (MluI and BamHI for MT145; MluI and 
NotI for EK505 and MB897, respectively). Full-length genomes were cloned 
into pCRXL (MT145 and EK505) or pBR-MCS (MB897) vectors and propa-
gated in STBL2 cells (Life Technologies). The newly derived SIVcpzPtt clones 
have been submitted to the NIH Research and Reference Program, and their 
nucleotide sequence is available at GenBank (see Accession numbers). Site-
directed mutagenesis of Gag30 was performed by splice overlap extension 
PCR, and all constructs were verified by sequence analysis.
Phylogenetic analyses. Gag protein sequences were inferred from gag 
gene regions (HXB2 coordinates: 790-2280) of published nucleotide 
sequences (HIV-1 M/A: M62320; HIV-1 M/B: K03455; HIV-1 N: AJ006022 
and DQ017382; HIV-1 O: L20571 and L20587; HIV-1 P: GU111555 and 
HQ179987; SIVcpzANT: U42720; SIVcpzCAM13: AY169968; SIVcpz-
CAM5: AJ271369; SIVcpzDP943: EF535993; SIVcpzEK505: DQ373065; 
SIVcpzMB897: EF535994; SIVcpzMT145: DQ373066; SIVcpzTAN1: 
AF447763; SIVcpzTAN2: DQ374657; SIVcpzTAN3: DQ374658; SIVcpz-
TAN5: JN091691; SIVcpzUG38: JN091690; SIVcpzUS: AF103818; SIVgor-
CP684: FJ424871) and aligned using ClustalW (56). A maximum likelihood 
phylogeny with bootstrap support was determined using PhyML (57) using 
an LG+I+G evolutionary model (58) as favored by ProtTest (59).
Viral infectivity and replication. Virus stocks were generated by transient 
transfection of 293T cells, and infectivity assays were performed using 
TZM-bl indicator cells as described (60).
Human and chimpanzee CD4+ T lymphocyte cultures. CD4+ T lymphocytes 
from human or chimpanzee donors were purified from total PBMCs by 
positive selection, activated using Staphylococcal enterotoxin B, and sub-
sequently cocultured with autologous monocyte-derived macrophages to 
achieve optimal activation as described (6, 18, 61). After 5 to 6 days, 5 × 105 
activated CD4+ T cells were infected at an MOI of 0.1 (as determined using 
TZM-bl cells) using transfection-derived viral stocks. The RT activity in cul-
ture supernatants was measured every 3 days to monitor viral replication.
Infection of HLT ex vivo. Human tonsils removed during routine tonsillec-
tomies were dissected into 2- to 3-mm3 blocks, cultured, and infected with 
viral stocks normalized based on p24 content as described previously (20, 21, 
40). Productive HIV-1 and SIVcpz infection were evaluated by measuring the 
amount of p24 core antigen released into the medium using the InnoTest 
HIV Antigen mAb ELISA (Innotest HIV Antigen mAb; Innogenetics). This 
ELISA recognizes the p24 proteins of divergent SIVcpz and HIV-1 strains with 
equal efficiency, and all results on viral replication were verified by RT assay.
Competition assay in HLT. The tonsil blocks were each coinfected with 
stocks of WT and mutant virus containing 0.5 ng of p24 antigen. Every 
2 to 3 days, the medium of the histoculture was replaced. After 2 weeks, 
the culture medium was collected and RT-PCR (SuperScript III One-Step 
RT-PCR with Platinum Taq; Invitrogen) was performed to amplify viral 
genomic RNA using primers flanking the Gag30 coding region in the p17 
matrix proteins. The PCR fragments were purified from agarose gels and 
examined by direct sequence analysis.
Competition assay in human T cells. Pairwise competition experiments were per-
formed using human T cell–derived virus stocks to optimize target cell infec-
tion. Briefly, 293T cell–derived transfection supernatants were used to infect 
Staphylococcal enterotoxin B–activated human CD4+ lymphocytes, superna-
tants were collected at the replication peak (6 to 8 days after infection), and 
the virus titer was determined using the Innotest HIV Antigen mAb ELISA. 
For virus competition in human T cell culture, 1 million activated CD4+ lym-
phocytes were coinfected for 2 hours in 500 μl medium containing 12.5 ng of 
p24 for the WT and Gag30 mutant T cell–derived virus stocks. Cells were then 
washed 3 times and plated in 2 ml of complete medium (RPMI + 10% FCS +30 
IU IL-2). Supernatants were collected on days 3, 5, 7, and 9 after infection to 
monitor virus replication, and the cell culture supernatants collected at 7 days 
after infection were used to analyze the outcome of the competition by direct 
sequencing of gag PCR products as described above. Cytopathic effects of viral 
replication precluded the meaningful analysis of later time points.
Accession numbers. GenBank accession numbers of newly generated SIVcpz 
clones are as follows: JN835460 (EK505clone2), JN835461 (MB897FL-
clone2), and JN835462 (MT145clone2).
Study approval. Chimpanzee blood samples were collected from captive indi-
viduals housed at the Yerkes National Primate Research Center during their 
annual health survey, a procedure approved by the Emory Institutional Animal 
Care and Use Committee. Studies involving human material were reviewed and 
approved by the University of Ulm Institutional Review Board, and individuals 
provided informed consent prior to donating blood or tonsillary tissue.
Statistics. Statistical calculations were performed using 2-tailed unpaired 
(for comparison of different groups) or paired (to assess the impact of 
mutations in Gag30) Student’s t tests using Graph Pad Prism Version 5.0. 
P < 0.05 was considered significant. Correlations were calculated with the 
linear regression module.
Acknowledgments
We thank Matthias H. Kraus, Rebecca S. Rudicell, Martha Mayer, 
and Birgit Ott for technical assistance. This work was supported 
in part by the NIH (R21 AI080364, R01 AI50529, R01 AI58715, 
P30 AI27767), the Yerkes Regional Primate Research Center (RR-
000165), the Bristol Myers Freedom to Discover Program, and the 
Deutsche Forschungsgemeinschaft.
Received for publication October 11, 2011, and accepted in revised 
form March 5, 2012.
Address correspondence to: Beatrice H. Hahn, Departments of 
Medicine and Microbiology, Perelman School of Medicine, Uni-
versity of Pennsylvania, Philadelphia, Pennsylvania 19104-6060, 
USA. Phone: 215.746.8515; Fax: 215.573.8976; E-mail: bhahn@
upenn.edu. Or to: Frank Kirchhoff, Institute of Molecular Virol-
ogy, Ulm University Medical Center, Meyerhofstrasse 1, 89081 
Ulm, Germany. Phone: 49.731.50065150; Fax: 49.731.50065153; 
E-mail: frank.kirchhoff@uni-ulm.de.
research article
1652	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 122   Number 5   May 2012
 1. Sharp PM, Hahn BH. Origins of HIV and the AIDS 
pandemic. Cold Spring Harb Perspect Med. 2011; 
1(1):a006841.
 2. Van Heuverswyn F, et al. SIV infection in wild goril-
las. Nature. 2006;444(7116):164.
 3. Keele BF, et al. Chimpanzee reservoirs of pan-
demic and nonpandemic HIV-1. Science. 2006; 
313(5786):523–526.
 4. Plantier JC, et al. A new human immunode-
ficiency virus derived from gorillas. Nat Med. 
2009;15(8):871–872.
 5. Vallari A, et al. Confirmation of putative HIV-1 group 
P in Cameroon. J Virol. 2011;85(3):1403–1407.
 6. Takehisa J, et al. Origin and biology of sim-
ian immunodeficiency virus in wild-living western 
gorillas. J Virol. 2009;83(4):1635–1648.
 7. Mauclere P, et al. Serological and virological char-
acterization of HIV-1 group O infection in Camer-
oon. AIDS. 1997;11(4):445–453.
 8. Peeters M, et al. Geographical distribution of HIV-1 
group O viruses in Africa. AIDS. 1997;11(4):493–498.
 9. Vallari A, et al. Four new HIV-1 group N isolates 
from Cameroon: Prevalence continues to be low. 
AIDS Res Hum Retroviruses. 2010;26(1):109–115.
 10. Delaugerre C, De Oliveira F, Lascoux–Combe C, 
Plantier J–C, Simon F. HIV–1 group N: travelling 
beyond Cameroon. Lancet. 2011;378(9806):1894.
 11. Kirchhoff F. Immune evasion and counteraction 
of restriction factors by HIV-1 and other primate 
lentiviruses. Cell Host Microbe. 2010;8(1):55–67.
 12. Bushman FD, et al. Host cell factors in HIV replica-
tion: meta-analysis of genome-wide studies. PLoS 
Pathog. 2009;5(5):e1000437.
 13. Ortiz M, Bleiber G, Martinez R, Kaessmann H, Telen-
ti A. Patterns of evolution of host proteins involved 
in retroviral pathogenesis. Retrovirology. 2006;3:11.
 14. Longdon B, Hadfield JD, Webster CL, Obbard DJ, 
Jiggins FM. Host phylogeny determines viral per-
sistence and replication in novel hosts. PLoS Pathog. 
2011;7(9):e1002260.
 15. Streicker DG, Turmelle AS, Vonhof MJ, Kuzmin IV, 
McCracken GF, Rupprecht CE. Host phylogeny con-
strains cross-species emergence and establishment of 
rabies virus in bats. Science. 2010;329(5992):676–679.
 16. The Chimpanzee Sequencing and Analysis Consor-
tium. Initial sequence of the chimpanzee genome 
and comparison with the human genome. Nature. 
2005;437(7055):69–87.
 17. McLean CY, et al. Human-specific loss of regula-
tory DNA and the evolution of human-specific 
traits. Nature. 2011;471(7337):216–219.
 18. Wain LV, et al. Adaptation of HIV-1 to its human 
host. Mol Biol Evol. 2007;24(8):1853–1860.
 19. Mwaengo DM, Novembre FJ. Molecular cloning and 
characterization of viruses isolated from chimpan-
zees with pathogenic human immunodeficiency virus 
type 1 infections. J Virol. 1998;72(11):8976–8987.
 20. Glushakova S, Baibakov B, Margolis LB, Zim-
merberg J. Infection of human tonsil histocul-
tures: a model for HIV pathogenesis. Nat Med. 
1995;1(12):1320–1322.
 21. Glushakova S, et al. Nef enhances human immu-
nodeficiency virus replication and responsiveness 
to interleukin-2 in human lymphoid tissue ex vivo. 
J Virol. 1999;73(5):3968–3974.
 22. Takehisa J, et al. Generation of infectious molecu-
lar clones of simian immunodeficiency virus from 
fecal consensus sequences of wild chimpanzees. 
J Virol. 2007;81(14):7463–7475.
 23. Van Heuverswyn F, et al. Genetic diversity and phylo-
geographic clustering of SIVcpzPtt in wild chimpan-
zees in Cameroon. Virology. 2007;368(1):155–171.
 24. Adachi A, et al. Production of acquired immunode-
ficiency syndrome-associated retrovirus in human 
and nonhuman cells transfected with an infectious 
molecular clone. J Virol. 1986;59(2):284–291.
 25. Papkalla A, Münch J, Otto C, Kirchhoff F. Nef 
enhances human immunodeficiency virus type 1 
infectivity and replication independently of viral 
coreceptor tropism. J Virol. 2002;76(16):8455–8459.
 26. Ghosh SK, et al. A molecular clone of HIV-1 tropic 
and cytopathic for human and chimpanzee lym-
phocytes. Virology. 1993;194(2):858–864.
 27. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, 
Hahn BH. Molecular characterization of human 
immunodeficiency virus type 1 cloned directly 
from uncultured human brain tissue: identifica-
tion of replication-competent and -defective viral 
genomes J Virol. 1991;65(8):3973–3985.
 28. Li Y, et al. Complete nucleotide sequence, genome 
organization, and biological properties of human 
immunodeficiency virus type 1 in vivo: evidence for 
limited defectiveness and complementation. J Virol. 
1992;66(11):6587–6600.
 29. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, 
Vinters HV, Chen IS. Dual infection of the central 
nervous system by AIDS viruses with distinct cel-
lular tropisms. Science. 1987;236(4803):819–822.
 30. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, 
Kabat D. Effects of CCR5 and CD4 cell surface 
concentrations on infection by macrophagetropic 
isolates of human immunodeficiency virus type 1. 
J Virol. 1998;72(4):2855–2864.
 31. Wei X, et al. Emergence of resistant human immu-
nodeficiency virus type 1 in patients receiving 
fusion inhibitor (T-20) monotherapy. Antimicrob 
Agents Chemother. 2002;46(6):1896–1905.
 32. Schoggins JW, et al. A diverse range of gene prod-
ucts are effectors of the type I interferon antiviral 
response. Nature. 2011;472(7344):481–485.
 33. Bushman FD, et al. Host cell factors in HIV replica-
tion: meta-analysis of genome-wide studies. PLoS 
Pathog. 2009;5(5):e1000437.
 34. Jäger S, et al. Global landscape of HIV-human pro-
tein complexes. Nature. 2011;481(7381):365–370.
 35. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits ret-
rovirus release and is antagonized by HIV-1 Vpu. 
Nature. 2008;451(7177):425–430.
 36. Van Damme N, et al. The interferon-induced pro-
tein BST-2 restricts HIV-1 release and is downregu-
lated from the cell surface by the viral Vpu protein. 
Cell Host Microbe. 2008;3(4):245–252.
 37. Jia B, et al. Species-specific activity of SIV Nef and 
HIV-1 Vpu in overcoming restriction by tetherin/
BST2. PLoS Pathog. 2009;5(5):1000429.
 38. Sauter D, et al. Tetherin-driven evolution of Vpu 
and Nef function and the emergence of pandemic 
and non-pandemic HIV-1 strains. Cell Host Microbe. 
2009;6(5):409–421.
 39. Zhang F, et al. Nef proteins from simian immuno-
deficiency viruses are tetherin antagonists. Cell Host 
Microbe. 2009;6(1):54–67.
 40. Rücker E, Grivel JC, Münch J, Kirchhoff F, Margolis 
L. Vpr and Vpu are important for efficient human 
immunodeficiency virus type 1 replication and 
CD4+ T-cell depletion in human lymphoid tissue 
ex vivo. J Virol. 2004;78(22):12689–12693.
 41. Yang SJ, Lopez LA, Exline CM, Haworth KG, Can-
non PM. Lack of adaptation to human tetherin in 
HIV-1 group O and P. Retrovirology. 2011;8:78.
 42. Sauter D, et al. HIV-1 Group P is unable to 
antagonize human tetherin by Vpu, Env or Nef. 
Retrovirology. 2011;8:103.
 43. Rudicell RS, et al. High prevalence of simian immuno-
deficiency virus infection in a community of savanna 
chimpanzees. J Virol. 2011;85(19):9918–9928.
 44. Hearps AC, Jans DA. Regulating the functions of 
the HIV-1 matrix protein. AIDS Res Hum Retrovi-
ruses. 2007;23(3):341–346.
 45. Bukrinskaya A. HIV-1 matrix protein: a myste-
rious regulator of the viral life cycle. Virus Res. 
2007;124(1–2):1–11.
 46. Batonick M, Favre M, Boge M, Spearman P, Hon-
ing S, Thali M. Interaction of HIV-1 Gag with 
the clathrin-associated adaptor AP-2. Virology. 
2005;342(2):190–200.
 47. Camus G, et al. The clathrin adaptor complex AP-1 
binds HIV-1 and MLV Gag and facilitates their bud-
ding. Mol Biol Cell. 2007;18(8):3193–3203.
 48. Dong X, et al. AP-3 directs the intracellular traffick-
ing of HIV-1 Gag and plays a key role in particle 
assembly. Cell. 2005;120(5):663–174.
 49. Tang Y, et al. Cellular motor protein KIF-4 
associates with retroviral Gag. J Virol. 1999; 
73(12):10508–10513.
 50. Ghanam RH, Fernandez TF, Fledderman EL, Saad 
JS. Binding of calmodulin to the HIV-1 matrix pro-
tein triggers myristate exposure. J Biol Chem. 2010; 
285(53):41911–41920.
 51. Lopez-Verges S, Camus G, Blot G, Beauvoir R, Bena-
rous R, Berlioz-Torrent C. Tail-interacting protein 
TIP47 is a connector between Gag and Env and is 
required for Env incorporation into HIV-1 virions. 
Proc Natl Acad Sci U S A. 2006;103(40):14947–14952.
 52. Cimarelli A, Luban J. Translation elongation fac-
tor 1-alpha interacts specifically with the human 
immunodeficiency virus type 1 Gag polyprotein. 
J Virol. 1999;73(7):5388–5401.
 53. Gupta K, Ott D, Hope TJ, Siliciano RF, Boeke JD. A 
human nuclear shuttling protein that interacts with 
human immunodeficiency virus type 1 matrix is pack-
aged into virions. J Virol. 2000;74(24):11811–11824.
 54. Mansharamani M, et al. Barrier-to-autointegration 
factor BAF binds p55 Gag and matrix and is a host 
component of human immunodeficiency virus 
type 1 virions. J Virol. 2003;77(24):13084–13092.
 55. Samelson LE. Signal transduction mediated by the 
T cell antigen receptor: the role of adapter proteins. 
Annu Rev Immunol. 2002;20:371–394.
 56. Larkin MA, et al. Clustal W and Clustal X version 
2.0. Bioinformatics. 2007;23(21):2947–2948.
 57. Guindon S, Dufayard JF, Lefort V, Anisimova M, 
Hordijk W, Gascuel O. New algorithms and meth-
ods to estimate maximum-likelihood phylogenies: 
assessing the performance of PhyML 3.0. Syst Biol. 
2010;59(3):307–321.
 58. Le SQ, Gascuel O. An improved general amino 
acid replacement matrix. Mol Biol Evol. 2008; 
25(7):1307–1320.
 59. Abascal F, Zardoya R, Posada D. ProtTest: selection 
of best-fit models of protein evolution. Bioinformat-
ics. 2005;21(9):2104–2105.
 60. Münch J, et al. Nef-mediated enhancement of viri-
on infectivity and stimulation of viral replication 
are fundamental properties of primate lentiviruses. 
J Virol. 2007;81(24):13852–13864.
 61. Decker JM, et al. Effective activation alleviates 
the replication block of CCR5-tropic HIV-1 in 
chimpanzee CD4+ lymphocytes. Virology. 2009; 
394(1):109–118.
